Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | -856k | - |
| Gross profit | -856k | - |
| Net profit | -10.19m | - |
| EBITDA | -8.61m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €11.84m |
Number of shares | 163m |
52-week high/low | €0.44 - €0.0726 |
| Dividends | No |
Beta | 0.70 |
P/E ratio | -1.03 |
PEG ratio | -0.02 |
P/B ratio | -0.50 |
P/S ratio | -13.54 |
Company profile
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
| Name | GENSIGHT BIOLOG. EO -,025 |
| CEO | Laurence Rodriguez |
| Headquarters | Paris,
if France |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 13/07/2016 |
| Employees | 13 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | SIGHT.PA |
Pnk | GSGTF |
Frankfurt | G49N.F |
Düsseldorf | G49N.DU |
London | 0RIM.L |
Paris | SIGHT.PA |
München | G49N.MU |